HRH4 and Alzheimer disease: A potent and selective H4R antagonist, LEO 152020 tablet (Figure 3b and Figure 4b), is currently being tested in a phase 2 clinical trial compared with placebo tablets for up to 16 weeks in the treatment of 224 adult participants with moderate to severe AD.